Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tryp Therapeutics Inc (TRYP.CN)

Tryp Therapeutics Inc (TRYP.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tryp Therapeutics Inc c/o Pushor Mitchell LLP, 301 - 1665 Ellis Street Kelowna BC V1Y 2B3 CAN

https://www.tryptherapeutics.com P: 833-811-8797

Description:

Tryp Therapeutics Inc is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, for the treatment of diseases with unmet medical needs. Tryp's program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. The company operates in two reportable segments; the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in the United States.

Key Statistics

Overview:

Market Capitalization, $K 6,267
Shares Outstanding, K 96,419
Annual Sales, $ 0 K
Annual Net Income, $ -5,267 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,161 K
60-Month Beta -1.60

Growth:

1-Year Return -33.33%
3-Year Return -91.18%
5-Year Return 0.00%

Per-Share Information:

Latest Earnings Date N/A
Earnings Per Share ttm -0.04
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -55.56%
Dividend Payout Ratio 0.00%

TRYP.CN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % -265.27%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book N/A
Book Value/Share -0.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar